Skin Cancer Long‑Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Patients with advanced melanoma who received nivolumab plus ipilimumab had the longest median overall survival (72.1 months) and melanoma‑specific survival (not reached) compared with nivolumab alone (36.9 months) or ipilimumab alone (19.9 months) over a 6.5‑year follow‑up period.
Prolonged survival can be attained in patients with melanoma treated with nivolumab plus ipilimumab or nivolumab alone with median overall survival of 72.1 and 36.9 months, and median melanoma‑specific survival not reached and 58.7 months, respectively. The majority of these patients are off therapy and have not yet started systemic subsequent therapy. yay
These long‑term results represent a substantial advance in the melanoma treatment landscape, providing evidence that dual immune checkpoint inhibition yields durable survival benefits beyond current standards, and underscoring the clinical relevance of melanoma‑specific survival metrics for guiding future therapeutic decisions.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies